Nature Reviews Drug Discovery contents October 2013 Volume 12 Number 10 pp 721-808

TABLE OF CONTENTS
October 2013 Volume 12 Number 10
Impact Factor 33.078 *	In this issue Comment News and Analysis Research Highlights Perspectives Reviews Also this month  Featured article: Considerations for the successful co-development of targeted cancer therapies and companion diagnostics Jane Fridlyand, Richard M. Simon, Jessica C. Walrath, Nancy Roach, Richard Buller, David P. Schenkein, Keith T. Flaherty, Jeff D. Allen, Ellen V. Sigal & Howard I. Scher
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
What do NASA, stem cells and Alzheimer's disease have in common? Find out at the Cell-based Assays Summit this December in Munich. Experts from the Johnson Space Centre, Roche, AbbVie and Janssen, join these dots to illustrate game-changing innovations for drug discovery, toxicity testing and disease modelling.   Learn more at: www.assayssummit.com/nature
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
Nature Insight Tumour Heterogeneity Tumour heterogeneity has important clinical implications, as it can explain therapeutic resistance, but also point to novel strategies to effectively treat cancers in a more personalised manner.  Access the Insight free online for three months
In this issue p721 | doi:10.1038/nrd4146 Full Text
Comment: Externalizing research through adaptive frameworks Jane Bjorn Vedel, Alan Irwin & Peter Hongaard Andersen p723 | doi:10.1038/nrd4138 Adaptive approaches to collaborations between industry and academic research institutions can enable both parties to achieve their goals more effectively. Here, we discuss our experience with such approaches and suggest recommendations for addressing the associated management challenges. Full Text | PDF
NEWS AND ANALYSIS		Top
PARP inhibitors bounce back Ken Garber p725 | doi:10.1038/nrd4147 A series of setbacks almost caused the demise of PARP inhibitors, but four companies are now beginning pivotal trials of these agents in breast and ovarian cancer. PDF
NEWS IN BRIEF Understanding upfront payment trends p728 | doi:10.1038/nrd4148 PDF
NEWS IN BRIEF Outcomes trials indicate no cardiovascular risk for diabetes drug class p728 | doi:10.1038/nrd4149 PDF
NEWS IN BRIEF COPD combo success p728 | doi:10.1038/nrd4150 PDF
BIOBUSINESS BRIEFS Deal watch: AstraZeneca bets on FibroGen's anaemia drug Monica Hoyos Flight p730 | doi:10.1038/nrd4135 PDF
BIOBUSINESS BRIEFS Market watch: Upcoming market catalysts in Q4 2013 Stacey Fong p731 | doi:10.1038/nrd4136 PDF
PATENT WATCH India's patent ecosystem — encouraging strong patents or discouraging innovation? Charlotte Harrison p732 | doi:10.1038/nrd4139 PDF
AN AUDIENCE WITH Daniel Hayes p734 | doi:10.1038/nrd4137 Daniel Hayes discusses how to break the vicious cycle that is keeping biomarkers down. PDF
FROM THE ANALYST'S COUCH Pharmaceutical forecasting: throwing darts? Myoung Cha, Bassel Rifai & Pasha Sarraf p737 | doi:10.1038/nrd4127 Forecasting of the future commercial value of drugs is a crucial activity that affects many decisions by pharmaceutical companies. However, this analysis indicates that many forecasts are wrong, often substantially. PDF
RESEARCH HIGHLIGHTS Top Neurodegenerative diseases: New kinase targets for Alzheimer's disease p739 | doi:10.1038/nrd4132 PDF Anticancer drugs: Breaking a cancerous interaction p740 | doi:10.1038/nrd4130 PDF Cardiology: Bromodomain inhibition halts heart failure p740 | doi:10.1038/nrd4134 PDF Anticancer drugs: Stapled peptide reactivates p53 p741 | doi:10.1038/nrd4133 PDF Biotechnology: Rice-derived rotavirus antibody shows promise p742 | doi:10.1038/nrd4131 PDF IN BRIEF Computational chemistry: Designing optimal ligand-binding proteins | Infectious diseases: A new lead against drug-resistant tuberculosis | Viral diseases: An antibody that hits four paramyxoviruses | Affective disorders: Selectively targeting COX2 decreases anxiety PDF Drug Discovery JOBS of the week Medical Director, Global Drug Safety Product Leader (m / f) Merck Group Post-Doc position in electro-spinning: scaffolding and drug delivery for regenerative medicine applications Center for Nanomedicine and Tissue Enigneering Postdoctoral Research Fellow In the Areas of Controlled Drug Delivery and Biomaterials University of Manitoba Tenured or Tenure-Track (Assistant or Associate) Levels Harvard University Regulatory Systems Biology - Faculty Position California Institute of Technology More Science jobs from Drug Discovery EVENT Malaria Drug Development and Resistance Control 03.07.14 London, UK More science events from
PERSPECTIVES		Top
OPINION Considerations for the successful co-development of targeted cancer therapies and companion diagnostics Jane Fridlyand, Richard M. Simon, Jessica C. Walrath, Nancy Roach, Richard Buller, David P. Schenkein, Keith T. Flaherty, Jeff D. Allen, Ellen V. Sigal & Howard I. Scher p743 | doi:10.1038/nrd4101 Here, the authors discuss issues relating to the co-development of targeted cancer therapies and companion diagnostics that were not covered in depth in the draft guidance released by the US Food and Drug Administration in 2011. They propose potential strategies that will be useful to mitigate challenges and to help guide the future co-development of drugs and diagnostics. Abstract | Full Text | PDF | Supplementary information
REVIEWS		Top
New avenues for anti-epileptic drug discovery and development Wolfgang Löscher, Henrik Klitgaard, Roy E. Twyman & Dieter Schmidt p757 | doi:10.1038/nrd4126 Over the past decade, our understanding of the pathology of epilepsy and the causes of drug resistance has grown substantially, providing opportunities for the development of more effective anti-epileptic drugs (AEDs). Here, Loscher and colleagues discuss issues that may have hampered previous AED discovery and propose strategies for the development of improved epilepsy therapies that offer a compelling case for industry investment. Abstract | Full Text | PDF
Drug discovery for autism spectrum disorder: challenges and opportunities Anirvan Ghosh, Aubin Michalon, Lothar Lindemann, Paulo Fontoura & Luca Santarelli p777 | doi:10.1038/nrd4102 The development of drugs for autism spectrum disorder (ASD) is hampered by the limited understanding of its pathophysiology, the heterogeneity of its symptoms, a dearth of experimental models, and the lack of experience in clinical development. In this Review, Ghosh and colleagues present recent insights into the molecular underpinnings of ASD and how these have translated into new tools for drug development, and also new approaches to overcome the particular challenges in this field. Abstract | Full Text | PDF
Applying insights from biofilm biology to drug development — can a new approach be developed? Thomas Bjarnsholt, Oana Ciofu, Søren Molin, Michael Givskov & Niels Høiby p791 | doi:10.1038/nrd4000 Bacteria that grow as aggregates in biofilms, in contrast to planktonic bacteria, are significantly more resistant to most antibiotics and microbicides. Chronic infections with such biofilms — for example, on implants, wounds and in the lungs of patients with cystic fibrosis — pose a serious medical problem. In this Review, Bjarnsholt and colleagues discuss the biological properties of biofilms and how these can inform the development of drugs that are active against biofilm infections. Abstract | Full Text | PDF
Advertisement
nature.com webcasts Macmillan Science Communication presents a custom webcast on: Multi-omics in metabolic disease: investigating the potential to predict diabetes Friday October 11th 7am PDT / 10am EDT / 3pm BST / 4pm CEST  Register for the free webcast followed by our live Q & A session  Sponsored by:
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2012 Journal Citation Report (Thomson Reuters, 2013)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.